Allogene Therapeutics
ALLO
161 hedge funds and large institutions have $586M invested in Allogene Therapeutics in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 54 increasing their positions, 46 reducing their positions, and 32 closing their positions.
393% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $260K
47% more capital invested
Capital invested by funds: $398M → $586M (+$188M)
17% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 46
3.96% more ownership
Funds ownership: 73.64% → 77.6% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 170 → 161 (-9)
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.2M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$16.1M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$12M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.54M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$5.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$8.52M |
| 2 |
JP Morgan Chase
New York
|
-$7.2M |
| 3 |
Millennium Management
New York
|
-$7.17M |
| 4 |
Morgan Stanley
New York
|
-$4.61M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.92M |
ALLO Hedge Fund Activity: Q1 2024 in Review
161 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2024, worth a combined $586M — up 47% from $398M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ALLO and 23 opened new positions — a net loss of 9 holders — while 46 trimmed existing stakes and 54 added.
The largest buyer was State Street, adding an estimated $28.2M. The largest seller was Goldman Sachs, cutting an estimated $8.52M.
- 161 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2024, down from 170 in Q4 2023.
- Funds reported $586M of Allogene Therapeutics stock for Q1 2024, up 47% quarter-over-quarter.
- 23 funds opened new Allogene Therapeutics positions in Q1 2024 and 32 closed out, a net change of -9 holders.
- The largest Allogene Therapeutics buyer in Q1 2024 was State Street, an estimated $28.2M added.
- The largest Allogene Therapeutics seller in Q1 2024 was Goldman Sachs, an estimated $8.52M sold.
Based on aggregated 13F filings for Q1 2024.